Dr Lynch recently retired from clinical practice at the MD Anderson Cancer Center. He spent more than 30 years managing patients with FAP, HNPCC, and related conditions. He has conducted several chemoprevention trials, mainly in FAP. He has been active in governance of CGA and of InSiGHT over the years